Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments on Feb...
February 19 2020 - 8:30AM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
genetic medicine for rare diseases, will report fourth quarter and
full-year 2019 financial results after the Nasdaq Global Market
closes on Wednesday, February 26, 2020. Subsequently, at 4:30 p.m.
E.T., the Company will host a conference call to discuss its fourth
quarter and full-year 2019 financial results and to provide a
corporate update.
The conference call may be accessed by dialing
(844) 534-7313 for domestic callers and (574) 990-1451 for
international callers. The passcode for the call is 4749068. Please
specify to the operator that you would like to join the "Sarepta
Fourth Quarter and Full-Year 2019 Earnings Call." The conference
call will be webcast live under the investor relations section of
Sarepta's website at www.sarepta.com and will be archived there
following the call for 90 days. Please connect to Sarepta's website
several minutes prior to the start of the broadcast to ensure
adequate time for any software download that may be necessary.
About Sarepta
TherapeuticsSarepta is at the forefront of precision
genetic medicine, having built an impressive and competitive
position in Duchenne muscular dystrophy (DMD) and more recently in
gene therapies for limb-girdle muscular dystrophy diseases (LGMD),
Charcot-Marie-Tooth (CMT), MPS IIIA and other CNS-related
disorders, totaling over 20 therapies in various stages of
development. The Company’s programs and research focus span several
therapeutic modalities, including RNA, gene therapy and gene
editing. Sarepta is fueled by an audacious but important mission:
to profoundly improve and extend the lives of patients with rare
genetic-based diseases. For more information, please visit
www.sarepta.com.
Internet Posting of
Information
We routinely post information that may be
important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and
potential investors to consult our website regularly for important
information about us.
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Investors: Ian Estepan, 617-274-4052iestepan@sarepta.com
Media:Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Sep 2023 to Sep 2024